UAUchenna Blessing Alozieuwa

Uchenna Blessing Alozieuwa

*This is an algorithmically generated author record based on publicly available information.

Uchenna Blessing Alozieuwa has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ethnopharmacology, chemical constituents, and biological activities of Khaya senegalensis (Desr.) A. Juss a forest plant with multi-purpose applications

    by Isa Adamu, Abafi J. Majiyebo, Uchenna B. Alozieuwa, AbdulRafiu A. Lawal, Bernard O. Odey, Rahmatallah A. Alawode, Eustace B. Berinyuy

    Khaya senegalensis (Desr.) A. Juss. is a valuable medicinal plant with various pharmacological and therapeutic properties. Khaya senegalensis has been reportedly used in treating patients with urinary infections, diarrhea, and inflammation. It also has been used for the treatment of liver and kidney diseases. The chemical studies of the plant have revealed that various parts of the plant contain alkaloids, carbohydrates, proteins and amino acids, saponins, glycosides, quinones, flavonoids, terpenoids, etc. Various studies have shown that Khaya senegalensis plays a role in the prevention of cardiovascular disease, lowering blood glucose and serum lipid, decreasing blood pressure and strengthening the heart. This herb has anti-bacterial, anti-malaria, anti-fungal and anti-inflammatory effects. The present review, therefore, revealed that Khaya senegalensis is an important medicinal plant due to its traditional uses for the treatment of several diseases and the presence of many important bioactive compounds which have been implicated in the various pharmacological properties of the plant. Further experimental studies are needed to fully validate the medicinal properties.


  • In vivo antimalarial efficacy of Psidium guajava leaf crude extract and fractions in Plasmodium berghei infected mice

    by Uchenna Blessing Alozieuwa, Abdulahi Mann, Adamu Yusuf Kabiru, Emmannuel Olofu Ogbadoyi

    Background: Malaria is a life-threatening disease caused by the protozoan parasite, Plasmodium. The emergence of drug-resistant Plasmodium species to currently available antimalarials has necessitated the search for more effective drugs. This study evaluated the antimalarial potential of the crude extract and fractions of Psidium guajava leaf in Plasmodium berghei infected mice. Method: Mice infected with Plasmodium berghei (P. berghei) were administered orally with the crude extract and fractions at doses ranging from 100-500 and 50-200mg/kg/day respectively, for five consecutive days. Results: The crude extract significantly (p<0.05) inhibited parasite growth as well as prevented body weight loss and packed cell volume reduction dose-dependently. Among the fractions, aqueous fraction was the most active with 54.26% inhibition of parasite growth at 200mg/kg. Remarkable inhibition of parasite growth by the crude extract and aqueous fraction was evident in the prolongation of mice survival relative to the control (27.33±1.76, 24.67±0.67, 28.0±1.16 and 8.33±0.67 for crude extract (500mg/kg), aqueous fraction (200mg/kg), chloroquine and negative control groups respectively). Phytochemical screening of the crude extract revealed the presence of phenol, alkaloids, flavonoids, and terpenoids. Conclusion: The results indicate that crude extract and aqueous fraction of P. guajava leaf are potent antimalarial agent that can be employed in the development of antimalarial drugs.


  • Mexicanolide, a bioactive compound from Cedrela odorata: In silico study of its pharmacokinetics, drug-likeness, potential drug targets, and cytotoxic activities against cancer cell lines

    by Blessing U. Alozieuwa, Shehu U. Abdullahi, Abdulhakeem Rotimi Agboola, Bernard O. Odey, Adaaja B. Ovaiyoza, Otiwa G. Iyaji, Zaman E. Yuyu, Oloyede E. Olayinka, Dauda Muhammed, Eustace B. Berinyuy

    Mexicanolide is a limonoids type of compound identified from Cedrela odorata, a forest plant with various medicinal properties. Several biological activities have been reported for Mexicanolide. In the present study, we used an in silico approach to evaluate the physicochemical, pharmacokinetics, drug-likeness, drug targets, and cytotoxic activities of mexicanolide from Cedrela odorata. The results revealed that mexicanolide has favorable physicochemical and pharmacokinetic properties of a good drug-like candidate. Notably, the compound has a high GI absorption rate but could not permeate the blood-brain barrier (BBB) and has poor synthetic accessibility. Several proteins targets including Kappa Opioid receptor, Mu opioid receptor, delta-opioid receptor, Cannabinoid receptor 2, Phosphodiesterase 10A (by homology), Platelet-derived growth factor receptor-beta, Stem cell growth factor receptor, Vascular endothelial growth factor receptor 2, Proteinase-activated receptor 1, and Epoxide hydratase were identified as target candidates for mexicanolide. Furthermore, mexicanolide demonstrated in silico activities against several types of cancer cell lines including the SK-MEL-2, HL-60, 8505C, SF-268, St4, OVCAR-5, K562, SW-60, MKN-7, and Lu1. In conclusion, mexicanolide has favorable physicochemical and pharmacokinetic properties of a good drug-like candidate and could be considered a multi-target compound with potential anticancer activities


  • Azadirachtin-A a bioactive compound from Azadiracta indica is a potential inhibitor of SARS-CoV-2 main protease

    by Eustace Berinyuy, Jonathan Ibrahim, Blessing Alozieuwa

    Despite the growing scientific interest in finding effective treatment, SARS-CoV-2 virus remains a global major health burden and public health emergency. SARS-CoV main protease (Mpro) also known as chymotrypsin-like protease (3CLpro) is an important protein identified to be vital for SARS-CoV-2 survival. However, to date, there are no clinically approved drugs or antibodies specific for SARS-CoV-2. In the present study, we evaluated the interaction of 3CLpro with azadirachtin-A a bioactive compound from Azadiracta indica using in silico molecular docking study. Our results revealed that Azadiractin A docked well into the binding cavity of 3CLproSARS-CoV-2 with binding affinities ranges between -6.3 and -5.20 kcal/mol, and Pkd of 5.82~6.10 for the ten best binding modes. Azadiractin interacted with the active site of 3CLpro-SARS-CoV-2 by 2 conventional hydrogen bonding to HIS163 and GLU166, C-H interactions with HIS127, and alkyl interaction with PRO168 of the 3CLpro-SARS-CoV-2. We also found that the Azadiractin-A_3CLpro-SARS-CoV-2 complex is stabilized by various Vander wall forces with ASN142, LEU141, PHE140, MET165, GLN189, LEU167, THR190, and ALA191. In conclusion, our results suggested that Azadirachtin-A could be a potential inhibitor of SARS-CoV-2 main protease, thus worthy of further preclinical study.